Lexaria Bioscience Corp. has closed a $4.0 million registered direct offering, positioning the global drug delivery innovator to advance its 2026 research and development objectives. The company sold 2,666,667 shares of common stock at $1.50 per share through a registered direct offering priced at-the-market under Nasdaq rules, while concurrently issuing unregistered warrants for up to 2,666,667 additional shares in a private placement.
This financing provides critical capital for Lexaria's ongoing development of its DehydraTECH drug delivery platform, which improves how various drugs enter the bloodstream through oral delivery. The technology has demonstrated capabilities in increasing bio-absorption, reducing side effects, and enhancing drug delivery across the blood-brain barrier. With 50 patents granted worldwide and additional patents pending, this funding supports the company's robust intellectual property portfolio and research initiatives.
Chief Executive Officer Richard Christopher emphasized the strategic importance of this financing, stating it provides greater optionality for the company's 2026 R&D and business development plans. Most of Lexaria's study work requires signed contracts before initiation, making forward funding essential for planning and execution. The capital enables the company to bring its 2026 objectives into clearer focus while advancing research that drives both intellectual property development and corporate value creation.
H.C. Wainwright & Co. served as the exclusive placement agent for the offering, which generated approximately $4.0 million in gross proceeds before deducting placement agent fees and other offering expenses. The company intends to allocate net proceeds toward working capital and general corporate purposes, supporting continued innovation in drug delivery technology.
The registered shares were offered pursuant to a shelf registration statement on Form S-3 that was declared effective by the Securities and Exchange Commission on January 30, 2025. Investors can access the prospectus supplement and accompanying prospectus through the SEC's website at https://www.sec.gov. The concurrent private placement warrants were issued under Section 4(a)(2) of the Securities Act and Regulation D, carrying an exercise price of $1.37 per share with immediate exercisability and five-year expiration terms.
This capital infusion represents a significant milestone for Lexaria as it continues developing technology that could potentially transform oral drug delivery across multiple therapeutic areas. The funding supports the company's licensed in-house research laboratory operations and ongoing evaluation of future funding requirements. For additional information about Lexaria's technology and research programs, visit https://www.lexariabioscience.com.
